Argos Therapeutics Inc. is being coy about its financing plans after withdrawing its planned IPO on NASDAQ due to market conditions. But the company says it is going ahead next quarter with a $40-$50 million Phase III trial of its immunotherapy in renal cell carcinoma, even though its bank balance at Dec. 31 was just $2 million.